Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jun 7;28(25):4130-7. doi: 10.1016/j.vaccine.2010.04.026. Epub 2010 Apr 28.

Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue.

Author information

1
The Edward Jenner Institute for Vaccine Research, Compton, RG20 7NN, United Kingdom. bbaaten@sanfordburnham.org

Abstract

Influenza virus infection remains a major health concern due to morbidity and mortality associated with epidemics and occasional pandemics. The absence of acquired immunity to antigenically distinct, emerging virus strains stresses the need for a generic drug that protects independent of vaccination. Here, we demonstrate that prophylactic administration of chitin microparticles (CMP) via the intranasal route significantly reduced lung viral titres and clinical signs. Pre-treatment boosted the innate immune response to subsequent infection by recruiting innate cells, such as neutrophils, and increasing inflammatory cytokines. Although an increase in virus-specific T cells was observed, the memory phase was diminished. Our data demonstrate that in the absence of prior exposure to influenza virus, CMP reduce clinical signs by boosting innate immunity.

PMID:
20433805
DOI:
10.1016/j.vaccine.2010.04.026
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center